bottom line overweight rate agil reflect view
current growth challeng temporari growth
reacceler beyond report result
covid updat support thesi
revenu flat better expect report
result came assumpt street consensu
organ revenu declin despit overexposur chemic
 market total revenu compani april
perform declin posit signal
china recoveri china account total revenu saw
strong growth april end quarter growth
consist peer posit comment china perform
framework conserv allow downsid
environ manag provid framework organ
revenu rang believ framework
conserv biopharma busi remain resili market
doesnt seem deterior academic/govt exposur
earli indic onshor market first
compani mention suppli chain shift market due
pandem manag believ situat like
continu
model updat updat ep estim
 note herein increas
price target ebitda
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
conform compani non-gaap present exclud
ep conform compani non-gaap present exclud intang
compani data secur llc estim reuter
period end incom expens expens incom share share ep dilut per sale cash flowoper cash cash revenu marginnot conform compani non-gaap present exclud intang amort acquisit integr cost transform initi etc sourc secur llc estim compani report inc
price target
price target reflect enterpris valu use project level debt cash
ebitda ex option multipl slight premium median ev/ebitda
multipl tool peer group believ reason given prospect above-industri
growth downsid risk overweight rate includ limit global macro
deterior well deterior demand trend specif china given region
rel import growth furthermor slowdown demand compani
pharma/biotech industri would headwind growth final addit risk aris potenti lack
slowdown new product adopt demand disrupt outsourc nucleic acid activ
pharmaceut ingredi acquisit target select integr
overweight rate agil reflect view current growth challeng temporari
growth re-acceler beyond
consum servic life scienc appli industri clinic market rel peer
compani high exposur appli end market high exposur emerg market
compani oper three segment life scienc appli market group lsag agil
crosslab group acg diagnost genom group dgg lsag provid analyt tool
ga liquid chromatographi mass spectrometri atom spectroscopi instrument
softwar acg provid servic consum agil instrument well instrument
competitor dgg provid diagnost genom tool particular strength anatom
patholog cytogenet array sequenc sampl prep
